Tiblio
Sign Up

DRUG

Bright Minds Biosciences Inc
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$634.25M
P/E Ratio
—
EPS
$-2.41
Beta
0.10
52W High
$123.75
52W Low
$24.00
50-Day MA
$75.74
200-Day MA
$74.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—

About Bright Minds Biosciences Inc

Bright Minds Biosciences Inc. (DRUG) is a pioneering clinical-stage biotechnology company dedicated to creating innovative therapies for central nervous system disorders, with a strong focus on mental health and pain management. Harnessing its proprietary drug development platform, Bright Minds is advancing a diverse pipeline of treatments, strategically aligned with the growing acceptance of psychedelic therapies. The company's experienced management team and extensive intellectual property portfolio position it uniquely to capitalize on the surging demand for novel mental health solutions, representing a compelling investment opportunity for institutional investors in the dynamic pharmaceutical landscape.

Official WebsiteUSAFY End: September

Fundamentals

Revenue (TTM)0
Gross Profit (TTM)0
EBITDA—
Operating Margin0.00%
Return on Equity-15.00%
Return on Assets-10.40%
Revenue/Share (TTM)$0.00
Book Value$22.14
Price-to-Book3.06
Price-to-Sales (TTM)—
EV/Revenue-
EV/EBITDA-0.07
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$9.81M
Float$5.13M
% Insiders12.00%
% Institutions92.92%

Historical Volatility

HV 10-Day
65.95%
HV 20-Day
63.88%
HV 30-Day
67.15%
HV 60-Day
59.97%
HV Rank
44.0%

Volatility is currently contracting

Analyst Ratings

Consensus ($165.69 target)
1
Strong Buy
6
Buy

Latest News

Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows:

GlobeNewsWire5/26/2026Neutral

More HEALTHCARE Stocks

LLYEli Lilly and CompanyJNJJohnson & JohnsonABBVAbbVie IncUNHUnitedHealth Group IncorporatedMRKMerck & Company IncNVSNovartis AG ADRAZNAstraZeneca PLCNVONovo Nordisk A/SAMGNAmgen IncTMOThermo Fisher Scientific IncGILDGilead Sciences IncABTAbbott Laboratories
View all HEALTHCARE stocks →
Data last updated: 7/9/2026